Moderna cancer vaccine delays return of deadly skin cancer
An experimental mRNA vaccine developed by Moderna Inc MRNA.O combined with Merck & Co’s MRK.N blockbuster immunotherapy Keytruda cut the risk of death or recurrence of the most deadly skin cancer by 44% compared Keytruda alone, US researchers reported at a medical meeting on Sunday. The findings suggest that adding a personalized cancer vaccine based […]
Continue Reading